Cannara Biotech Inc remains stable as it navigates recent developments in the cannabis sector.
Cannara Biotech Inc (LOVE.V) has had a steady week, closing at C$1.99 with no significant price changes. This stability comes amid various strategic moves by the company.
Advertisement
Cannara Biotech Inc
LOVE.V
LOVE.V
Cannara Biotech Inc
WealthAwesomeMarket cap
$181.03M
P/E
15.8x
52W high
$2.07
52W low
$1.06
1W change
+0.00%
Beta
0.34
Analyst Price Targets
Based on analyst covering LOVE
Wall Street analysts forecast LOVE stock price to rise 69.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
+69.6% Upside
Current Price
C$1.99
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
47.9%
Annualized
90-Day Vol
42.2%
Annualized
Trend (90d)
+30.9%
Annualized drift
90d Mean
C$2.04
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.90 | C$1.61 โ C$2.24 |
| 60 trading days | C$1.97 | C$1.56 โ C$2.49 |
| 90 trading days | C$2.04 | C$1.54 โ C$2.72 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Keep an eye on Cannara's recent financial decisions and leadership changes, as these could signal future growth, even if the stock is currently stable.
Cannara Biotech Inc's stock has remained stable, closing at C$1.99 with a year-to-date gain of 2.81%.
The stock has traded within a 52-week range of C$1.06 to C$2.07, suggesting it is currently near the upper end of this range.
Bull case
The recent appointment of a new CFO and an expanded financing agreement could help Cannara improve its operational efficiency and create new growth opportunities.
Bear case
The lack of recent news might indicate a period of stagnation, raising concerns about the company's short-term momentum.
Recent Developments
Advertisement
Cannara Biotech has been active recently, making several significant announcements. On September 10, 2026, the company secured an $80 million syndicated credit facility with BMO and TD Bank, enhancing its financial flexibility. Additionally, the appointment of Nicholas Fozard as Chief Financial Officer on September 1, 2026, brings fresh leadership to the financial team. Cannara also implemented an Automatic Share Purchase Plan on August 13, 2026, to optimize share repurchases and initiated a Normal Course Issuer Bid on July 22, 2026. These steps reflect a proactive approach to strengthening the company's financial foundation.
Technical Picture
Cannara Biotech's stock is currently trading at C$1.99, above its 50-day moving average of C$1.81 and well above its 200-day moving average of C$1.69. With a beta of 0.34, the stock shows lower volatility compared to the market. The current price is within 92% of its 52-week range of C$1.06 to C$2.07, indicating it is trading near its higher end. The latest trading volume of 19,054 shares is notably below the 20-day average volume of 54,878 shares, suggesting reduced trading activity.
Market Position and Analyst Outlook
Cannara Biotech has a market capitalization of about C$181 million, with a price-to-earnings ratio of 15.75 and a profit margin of 10.5%. Analysts are optimistic, maintaining a bullish outlook with an average target price of C$3.38, which implies a potential upside of 69.6% from the current price. This positive sentiment is backed by the companyโs recent record Q3 financial performance, reflecting growth and profitability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
